170 related articles for article (PubMed ID: 16821629)
1. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
2. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
4. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
[TBL] [Abstract][Full Text] [Related]
5. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
6. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
[TBL] [Abstract][Full Text] [Related]
10. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
[TBL] [Abstract][Full Text] [Related]
13. Amifostine-related fever-rash during fractionated radiotherapy: diagnostic and predictive role of C-reactive protein.
Koukourakis MI; Pitsiava D; Giatromanolaki A; Kambouromiti G; Sivridis E; Kartalis G
Am J Clin Oncol; 2011 Jun; 34(3):281-5. PubMed ID: 20838325
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
[TBL] [Abstract][Full Text] [Related]
15. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
16. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Anacak Y; Kamer S; Haydaroglu A
Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
[TBL] [Abstract][Full Text] [Related]
17. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
18. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
19. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
Kuechler A; Dreidax M; Pigorsch SU; Liehr T; Claussen U; Wendt TG; Dunst J
Strahlenther Onkol; 2003 Jul; 179(7):493-8. PubMed ID: 12835887
[TBL] [Abstract][Full Text] [Related]
20. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
